<DOC>
	<DOCNO>NCT00840333</DOCNO>
	<brief_summary>Patients cystic fibrosis ( CF ) suffer chronic infection low respiratory tract cause one multiple bacteria , include Pseudomonas aeruginosa , particularly problematic eradicate implicate major cause morbidity mortality CF patient . Aerosol delivery antibiotic directly lung increase local concentration antibiotic site infection result improve antimicrobial effect compare systemic administration . Bacterial resistance current aerosol antibiotic treatment indicate need improved therapy treat CF patient pulmonary infection cause multi-drug resistant Pseudomonas aeruginosa bacteria . High concentration MP-376 deliver directly lung project antimicrobial effect even resistant organism . MP-376 novel formulation fluoroquinolone levofloxacin optimize aerosol delivery use PARI electronic eFlow® nebulizer . Preclinical early clinical study adults show aerosol dos MP-376 appear safe well tolerate , exert antimicrobial effect administer twice daily . High concentration levofloxacin lung deliver use MP-376 expect active CF pathogens P. aeruginosa S. aureus , include resistant aminoglycosides ( TOBI® ) inhale antimicrobial agent . Inhaled MP-376 deliver rapidly efficiently use PARI eFlow® nebulizer system . This Phase 1 study perform obtain safety , tolerability PK data child age 6-16 order determine MP-376 safe , prior enrol child age plan pivotal Phase 3 study .</brief_summary>
	<brief_title>`` Safety , Tolerability Pharmacokinetics MP-376 Administered 14 Days Stable Pediatric ( CF ) Patients ''</brief_title>
	<detailed_description>A Phase 1B , Multi-Center , Open Label Study Evaluate Safety , Tolerability Pharmacokinetics MP-376 Inhalation Solution give Daily 14 Days Stable Pediatric Cystic Fibrosis Patients .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Inclusion Criteria ( select ) : 6 16 year age ( inclusive ) Visit 1 Weight great equal 14 kilogram ( kg ) Confirmed Diagnosis Cystic Fibrosis Patients able elicit FEV1 &gt; /= 25 % predict value ( Wang criterion ) Clinically stable change health status within last 14 day Able reproducibly undergo spirometry test Exclusion Criteria ( select ) : Use nebulized systemic antibiotic within 7 day prior baseline History intolerance hypersensitivity fluoroquinolones intolerance aerosol medication include bronchodilator CrCl &lt; 50mL/min/1.73m2 , AST , ALT total bilirubin &gt; /= 3 x ULN Screening evidence severe liver disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>